|
Name |
Chaetoglobosin A
|
Molecular Formula | C32H36N2O5 | |
IUPAC Name* |
(1R,3E,6R,7Z,9S,11E,13R,14S,16R,17S,18R)-6-hydroxy-19-(1H-indol-3-ylmethyl)-7,9,16,17-tetramethyl-15-oxa-20-azatetracyclo[11.8.0.01,18.014,16]henicosa-3,7,11-triene-2,5,21-trione
|
|
SMILES |
C[C@H]/1C/C=C/[C@H]2[C@H]3[C@](O3)([C@H]([C@@H]4[C@@]2(C(=O)/C=C/C(=O)[C@@H](/C(=C1)/C)O)C(=O)NC4CC5=CNC6=CC=CC=C65)C)C
|
|
InChI |
InChI=1S/C32H36N2O5/c1-17-8-7-10-22-29-31(4,39-29)19(3)27-24(15-20-16-33-23-11-6-5-9-21(20)23)34-30(38)32(22,27)26(36)13-12-25(35)28(37)18(2)14-17/h5-7,9-14,16-17,19,22,24,27-29,33,37H,8,15H2,1-4H3,(H,34,38)/b10-7+,13-12+,18-14-/t17-,19-,22-,24?,27-,28+,29-,31+,32+/m0/s1
|
|
InChIKey |
OUMWCYMRLMEZJH-ZFZZSEHSSA-N
|
|
Synonyms |
Chaetoglobosin A; 73AYL68TNX; NSC-366739; 50335-03-0
|
|
CAS | 50335-03-0 | |
PubChem CID | 165411882 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 528.6 | ALogp: | 3.7 |
HBD: | 3 | HBA: | 5 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 112.0 | Aromatic Rings: | 6 |
Heavy Atoms: | 39 | QED Weighted: | 0.302 |
Caco-2 Permeability: | -4.753 | MDCK Permeability: | 0.00001480 |
Pgp-inhibitor: | 0.998 | Pgp-substrate: | 0.048 |
Human Intestinal Absorption (HIA): | 0.018 | 20% Bioavailability (F20%): | 0.071 |
30% Bioavailability (F30%): | 0.188 |
Blood-Brain-Barrier Penetration (BBB): | 0.104 | Plasma Protein Binding (PPB): | 95.79% |
Volume Distribution (VD): | 0.29 | Fu: | 2.66% |
CYP1A2-inhibitor: | 0.053 | CYP1A2-substrate: | 0.389 |
CYP2C19-inhibitor: | 0.676 | CYP2C19-substrate: | 0.566 |
CYP2C9-inhibitor: | 0.635 | CYP2C9-substrate: | 0.139 |
CYP2D6-inhibitor: | 0.157 | CYP2D6-substrate: | 0.148 |
CYP3A4-inhibitor: | 0.944 | CYP3A4-substrate: | 0.404 |
Clearance (CL): | 4.45 | Half-life (T1/2): | 0.458 |
hERG Blockers: | 0.208 | Human Hepatotoxicity (H-HT): | 0.904 |
Drug-inuced Liver Injury (DILI): | 0.54 | AMES Toxicity: | 0.108 |
Rat Oral Acute Toxicity: | 0.779 | Maximum Recommended Daily Dose: | 0.912 |
Skin Sensitization: | 0.154 | Carcinogencity: | 0.076 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.007 |
Respiratory Toxicity: | 0.928 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002120 | 0.840 | D01TSI | 0.268 | ||||
ENC003586 | 0.802 | D0V3ZA | 0.261 | ||||
ENC006149 | 0.787 | D09NNH | 0.254 | ||||
ENC002440 | 0.779 | D0SP3D | 0.254 | ||||
ENC004470 | 0.744 | D02DMQ | 0.247 | ||||
ENC003226 | 0.722 | D0W7WC | 0.247 | ||||
ENC002646 | 0.708 | D0BV3J | 0.246 | ||||
ENC004465 | 0.703 | D05EJG | 0.238 | ||||
ENC003229 | 0.669 | D0NG7O | 0.225 | ||||
ENC002166 | 0.664 | D0R5OS | 0.224 |